Clinical Trial

Antigen-specific T Cells Against Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-11-24; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2018-01-01
Trial Details
NCT Number NCT03356808
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Lung Cancer
Enrollment 20 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23